Novavax Shares Up 16.3% as Q1 Loss Estimate Improves 9.2%
Novavax shares surged 16.3% over the past month while the biomedical and genetics sector gained 17.8%. Consensus estimates now project a Q1 loss of $0.32 per share (–110.9% YoY) after a 9.2% upward revision in 30 days and a next-year EPS forecast of $0.51.
1. Recent Share Performance
Shares of Novavax climbed 16.3% over the past month compared with a 17.8% gain in the broader biomedical and genetics sector, reflecting heightened investor focus on its near-term prospects.
2. Q1 Earnings Estimate Revisions
Analysts revised the Q1 earnings estimate to a loss of $0.32 per share, marking a 9.2% upward adjustment in the past 30 days despite a 110.9% year-over-year decline.
3. Full-Year Forecasts
The current fiscal year EPS consensus of –$0.17 per share (a 106.6% drop YoY) was raised 19.9% in the last month, while next fiscal year’s EPS forecast of $0.51 per share (198.3% below last year) saw a 1.2% uplift.
4. Valuation and Proprietary Rank
Valuation metrics place Novavax at par with peers (Value Style Score: C), and its proprietary rank of #3 suggests expected performance in line with the broader market.